Renovis Development Decision Clause Samples

Renovis Development Decision. In the event that Renovis wishes to pursue pre-clinical and clinical development of any Renovis Product, then Renovis, working together with Genentech, may develop and propose to the JRC a development plan (each, a “Renovis Plan”) for such Renovis Product in one or more indications in the Renovis Field. Within forty five (45) days of delivery of such Renovis Plan to the JRC, the JRC shall either approve such plan or reject it with a description of any additions or modifications to the plan that the JRC reasonably requires in good faith before granting approval. Prior to the development of any Renovis Product, Renovis must resubmit each Renovis Plan to the JRC until the JRC approves such plan. Unless and until such time as Genentech exercises its IND Opt-in, Renovis shall have responsibility for undertaking the pre-clinical development of each Renovis Product at its cost, provided that the JRC shall have ultimate decision-making authority on such matters, with the exception of decisions relating to manufacturing in the event that Genentech exercises its right to manufacture in accordance with Section 5.4. If Renovis decides not to pursue development of a Renovis Product within such eighteen (18) months of the designation thereof, such Renovis Product will be redesignated a Compound for purposes of this Agreement, so that if Renovis later desires to pursue development of such Compound, the JRC must re-review such Compound in accordance with Section 4.1.